AGC management based on ASCCP 2020

Dr Farah Farzaneh

Prof. Gyn.Oncology SBMU, 30/11/99

AGC

AGC on cytology

poorly reproducible Dx category

- ► HPV pos, (es.18),
 - higher risk of CIN 2+
- Colp is recommended for all
 regardless of HPV result

AGC

- AGC can be associated with
 - ▶ polyps
 - ▶ metaplasia
 - Adenoca of the cx;
 - ► Ca of the En, FT, Ov, other sites,
 - especially in older women with neg HPV

Cytology: AGC or AIS...

► Colp

recommended regardless of HPV test result

▶all ages

all subcategories of AGC and AIS,except when AEC specified

► ECC

recommended at initial colp

except in preg

Cytology: AGC, AIS...

- triage by reflex HPV testing
 - not recommended
- triage by repeat cytology
 - ▶ unacceptable
- Endometrial sampling
 - Recommended if nonpregnant
 - ▶≥ 35 yrs; all categories of AGC & AIS
 - < 35 yrs at increased risk of En neoplasia</p>
 - clinical indications (AUB, chronic anovulation, obesity)

Cytology: AGC or AIS ...

- If atypical En cells specified
 - initial evaluation limited to En and Endocx sampling is preferred,
 - colp acceptable at the time of initial evaluation
 - ▶ If no endometrial pathology at the first En sampling
 - Colp recommended



FIGURE 3. This figure describes the initial workup of AGC found on cervical cytology.

© 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the ASCCP.

Cytology: AGC, AIS colpo Bx

Colp Bx: No HSIL (CIN2+), no AIS, no ca:

If initial cytology:

AGC- NOS or AEC-NOS

cotesting at 1&2 yrs

Any abnormality:

colpo



Cytology: AGC, AIS colpo

Colp Bx: No AIS or Ca

If initial cytology:

AGC (favor neoplasia), or AIS

Dx Excisional Procedure

(intact specimen+ interpretable margins)

(ECC above excision bed preferred)

- Why AGC (favor neoplasia), adenoca in cytology are so important
 Frequently indicative of invasive or preinvasive disease
 even if HSIL or AIS not been identified
- En ca is rare in premenopause without risk factors
- The prevalence of premenopausal En ca is increasing
- The importance of En sampling when indicated

- Cytologic AGC results are associated with a histologic Dx of:
 - ► AIS in 3-4%,
 - ► CIN 2+ in 9%,
 - ▶ invasive ca in 2-3%.

- In the KPNC data,
 - ► HPV-pos AGC (all categories):
 - immediate CIN 3+ risk of 26%
 - ► HPV-neg AGC:
 - ▶ immediate CIN 3+ risk of 1.1%.

Consistent with other literature,
 HPV-pos AGC favor neoplasia or adenoca
 immediate CIN 3+ risk of 55%,
 other HPV-positive AGC categories
 immediate CIN 3+ risks of 20%.



FIGURE 4. This figure describes follow-up management that should occur after the diagnostic examinations described in Figure 3.

- **For All patients with a Dx of AIS on Cx Bx**
- A Dx excisional procedure is recommended
 - ► To R/O invasive adenoca
 - even when definitive hysterectomy is planned.
- Excisional procedures should optimally remove an intact specimen
 - ▶ to facilitate accurate interpretation of margin status.
- ▶ no preference for CKC vs LEEP,

Unacceptable

▶ intentional disruption of the specimen by LEEP, "top hat" endocx excision

- An excisional specimen length of
 - ▶ at least 10 mm is preferred
 - ▶ 18-20 mm if completed family planning
 - Regardless of whether hysterectomy is planned.

After the initial Dx procedure,

- hysterectomy is the preferred management for all patients
- who have a histologic Dx of AIS,
- Fertility-sparing management for appropriately selected patients is acceptable.

If confirmed AIS on the excisional specimen,
 with neg margins

simple hysterectomy is preferred.

with pos margins

re-excision to achieve neg margins is preferred

even if hysterectomy is planned.

with persistent pos margins & additional excisional procedures not feasible,

either a simple or modified rad hys is acceptable.

- In reproductive age, If desire future pregnancy:
 - ▶ 1- an excisional procedure is acceptable
 - provided neg margins have been achieved
 - the patient is willing/able to adhere to F/U recommendations.
 - 2-If neg margins not be achieved after max excisional attempts

>fertility-sparing management not recommended.



FIGURE 11. This figure describes management of AIS. This management algorithm was developed by the Society of Gynecologic Oncology and endorsed by the ASCCP Risk-Based Management Consensus process.

© 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the ASCCP.

Management of AIS Surveillance (SGO Recommendations)

- After hysterectomy
 - ASCCP guidelines for treated CIN 2+ is recommended
- If undergo fertility-sparing management,
 - Cotesting and ECC Q 6 mo for at least 3 yrs
 - then annually at least 2 yrs, or until hysterectomy performed.
 - ► If consistently neg cotesting and ECC for 5 yrs,
 - extending the surveillance interval to Q 3 yrs
 - starting in the sixth yr of surveillance is acceptable.

- Small retrospective studies have shown:
 - ► HPV test; the best predictor for recurrent disease.
 - ► If consistently neg cotesting and ECC
 - continued surveillance is acceptable after completion of childbearing
 - If pos HPV/abnormal cytology/histology surveillance,
 - hysterectomy at the completion of childbearing is preferred

Management of AIS; Why hysterectomy is the best (if no desire for fertility preservation)

1-AIS is frequently located within the endocx canal

- colpo changes may be minimal
- determination of the necessary length of a cx excisional specimen may be difficult
- 2-AIS has a higher risk of being multifocal,

Even neg margins, do not ensure complete excision of disease

► 3-Importantly, in the setting of histologic AIS on Bx

invasive ca cannot be excluded without a Dx excisional

► 4- AIS is not SCC

In SCC: increased detection/tr of SCC precursors (CIN 3) decreases the incidence of SCC

5-Because of the challenges in Dx and monitoring AIS

Management of AIS; Why hysterectomy is the best (if no desire for fertility preservation)

- For patients desiring future pregnancy,
 - observation after an excisional procedure remains an option
 - but carries <10% risk of recurrent AIS,</p>
 - ▶ a small risk of invasive ca even with neg margins.
 - Both margin status and ECC at the time of excisional procedure
 - predict residual disease/risk of invasive ca on hysterectomy specimen
 - After tr, HPV tests results are the strongest predictor for recurrent AIS

Case 1:37 yrs, NG, routine screening

- Cytology result
 - Atypical En Cell (AEC)
- Q1: Next step???
 - ► D&C
 - ► Colpo
 - ► ECC
 - ► HPV

Case 1: 37 yrs, NG, routine screening: AEC ► AQ1: D&C, ECC

Q2: no En pathology, next step?
Cotest in 3 mo
Tr by progesterone for 3 mo

► HPV reflex test



Case1: 37 yrs; NG; routine screening: AEC; D&C&ECC: no endometrial pathology

AQ2: Colposcopy

Q3: colpo result CIN 1, next step?

CKC

► LEEP

Cotest in 1 year

Copo in 6 mo

Case 1: 37 yrs; NG; routine screening: AEC; D&C&ECC: no En path; colpo:CIN1

- AQ3: Cotest in 1 year
- 37yrs NG
 Cytology: AEC
 D&C, ECC: no tissue
 Colpo: CIN1
 Cotest in 1 year

Case 2

- ► 31yr, NG, Mense reg, contraception WD,
- routine screening: AIS
- Colpo: No ca or AIS
- Excisional procedure
- AIS but margin neg and ECC pos
- Reexcision again margin pos
- Not possible for re excision, rad hys or simple hystrectomy